Akèy › Lukemi lenfositè kwonik › Ohio › Cincinnati
Etid klinik pou Lukemi lenfositè kwonik nan Cincinnati, OH
14 etid pou Lukemi lenfositè kwonik ap chèche patisipan nan sit nan ak bò kote Cincinnati (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Good Samaritan Hospital - Cincinnati, Cincinnati
- Oncology Hematology Care Inc-Kenwood, Cincinnati
- Bethesda North Hospital, Cincinnati
- ak 3 plis
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Ap rekriteFaz 3
- Oncology Hematology Care Clinical Trials, Llc, Cincinnati
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Ap rekriteFaz 3
- Saint Elizabeth Healthcare ( Site 0041), Edgewood · 8 mi lwen
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Ap rekriteFaz 4
- Oncology Hematology Care Inc, Cincinnati
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Ap rekriteFaz 3
- University of Cincinnati Medical Center, Cincinnati
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Ap rekriteFaz 2
- University of Cincinnati, Cincinnati
- Oncology Hematology Care, Fairfield · 15 mi lwen
A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
Ap rekriteFaz 1
- University of Cincinnati, Cincinnati
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Ap rekriteFaz 1
- University of Cincinnati Medical Center, Cincinnati
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Ap rekriteFaz 2
- Saint Elizabeth Medical Center Edgewood, Edgewood · 8 mi lwen
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Ap rekriteFaz 1
- Cincinnati Children's Hospital Medical Center, Cincinnati
- University of Cincinnati, Cincinnati
Study of Epcoritamab as a Consolidation Therapy in CLL/SLL
Ap rekriteFaz 2
- University of Cincinnati, Cincinnati
Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL
Ap rekriteFaz 2
- University of Cincinnati, Cincinnati
LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This
Ap rekriteFaz 2
- University of Cincinnati Medical Center, Cincinnati
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
Ap rekriteFaz 1/2
- University of Cincinnati, Cincinnati
Etid Lukemi lenfositè kwonik nan lòt vil
- Boston, MA31 etid
- Columbus, OH28 etid
- Durham, NC27 etid
- Washington, DC22 etid
- Seattle, WA20 etid
- Rochester, MN19 etid
- New York City, NY18 etid
- Houston, TX17 etid
- Baldwin Park, CA16 etid
- Milwaukee, WI15 etid
- Chicago, IL14 etid
- Nashville, TN13 etid
Lòt etid nan Cincinnati
- Kansè Poumon ki pa ti selil35 etid
- Kansè (tout kalite)27 etid
- Kansè nan tete25 etid
- Ensifizyans kadyak24 etid
- Kansè kolorektal21 etid
- Leksemi mieloïd egi20 etid
- Kansè Metastatik20 etid
- Kansè ovè19 etid
- Kansè poumon19 etid
- Obèsite19 etid
- Kansè pwostat18 etid
- Myelom Miltip17 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.